PT - JOURNAL ARTICLE AU - Tegally, Houriiyah AU - Wilkinson, Eduan AU - Giovanetti, Marta AU - Iranzadeh, Arash AU - Fonseca, Vagner AU - Giandhari, Jennifer AU - Doolabh, Deelan AU - Pillay, Sureshnee AU - San, Emmanuel James AU - Msomi, Nokukhanya AU - Mlisana, Koleka AU - von Gottberg, Anne AU - Walaza, Sibongile AU - Allam, Mushal AU - Ismail, Arshad AU - Mohale, Thabo AU - Glass, Allison J AU - Engelbrecht, Susan AU - Van Zyl, Gert AU - Preiser, Wolfgang AU - Petruccione, Francesco AU - Sigal, Alex AU - Hardie, Diana AU - Marais, Gert AU - Hsiao, Marvin AU - Korsman, Stephen AU - Davies, Mary-Ann AU - Tyers, Lynn AU - Mudau, Innocent AU - York, Denis AU - Maslo, Caroline AU - Goedhals, Dominique AU - Abrahams, Shareef AU - Laguda-Akingba, Oluwakemi AU - Alisoltani-Dehkordi, Arghavan AU - Godzik, Adam AU - Wibmer, Constantinos Kurt AU - Sewell, Bryan Trevor AU - Lourenço, José AU - Alcantara, Luiz Carlos Junior AU - Pond, Sergei L Kosakovsky AU - Weaver, Steven AU - Martin, Darren AU - Lessells, Richard J AU - Bhiman, Jinal N AU - Williamson, Carolyn AU - de Oliveira, Tulio TI - Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa AID - 10.1101/2020.12.21.20248640 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.21.20248640 4099 - http://medrxiv.org/content/early/2020/12/22/2020.12.21.20248640.short 4100 - http://medrxiv.org/content/early/2020/12/22/2020.12.21.20248640.full AB - Continued uncontrolled transmission of the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) in many parts of the world is creating the conditions for significant virus evolution. Here, we describe a new SARS-CoV-2 lineage (501Y.V2) characterised by eight lineage-defining mutations in the spike protein, including three at important residues in the receptor-binding domain (K417N, E484K and N501Y) that may have functional significance. This lineage emerged in South Africa after the first epidemic wave in a severely affected metropolitan area, Nelson Mandela Bay, located on the coast of the Eastern Cape Province. This lineage spread rapidly, becoming within weeks the dominant lineage in the Eastern Cape and Western Cape Provinces. Whilst the full significance of the mutations is yet to be determined, the genomic data, showing the rapid displacement of other lineages, suggest that this lineage may be associated with increased transmissibility.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.krisp.org.za/ngs-sa/ Funding StatementThis research reported in this publication was supported by the Strategic Health Innovation Partnerships Unit of the South African Medical Research Council, with funds received from the South African Department of Science and Innovation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was approved by University of KwaZulu-Natal Biomedical Research Ethics Committee. Protocol reference number: BREC/00001510/2020. Project title: Spatial and genomic monitoring of COVID-19 cases in South Africa. This project was also approved by University of the Witwatersrand Human Research Ethics Committee. Clearance certificate number: M180832. Project title: Surveillance for outpatient influenza-like illness and asymptomatic virus colonization in South Africa. Sequence data from the Western Cape was approved by the Stellenbosch University HREC Reference No: N20/04/008_COVID-19. Project Title: COVID-19: sequencing the virus from South African patients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genomic data has been deposited in GISAID